DSIP (delta sleep-inducing peptide) is one of the oldest peptides studied for sleep — first isolated from rabbit blood in 1974 and tested in human trials by the late 1970s. At TelosRX, compounded peptides are subject to medical approval by a licensed provider and are not FDA-approved.
Most sleep peptide articles summarize effects in two sentences and move on. This article takes a different approach: a structured look at what the published research actually found, study by study.
What Is DSIP? Background and Discovery
Delta sleep-inducing peptide is a nine-amino-acid neuropeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu). It was first isolated by Marcel Monnier and colleagues at the University of Basel from the blood of sleeping rabbits, after they observed that a dialysate from rabbit blood could induce delta-wave (slow-wave) sleep when infused into other rabbits.
The nonapeptide structure was later confirmed and synthesized. Since then, over 100 published studies have examined its effects on sleep, stress, pain, and cell biology across animal and human models.
DSIP is found naturally in the hypothalamus, limbic system, and pituitary. Its blood-brain barrier permeability — notably high for a peptide of its size — is one reason it attracted early research interest as a potential sleep modulator.
Finding 1: Early Human Trials on Sleep Architecture
The earliest human studies were conducted in the late 1970s and early 1980s at the University of Basel. Researchers administered synthetic DSIP intravenously to healthy volunteers and to patients with chronic sleep disorders.
Key observations from these trials:
- DSIP administration was associated with increased slow-wave (delta) sleep time in some participants.
- Sleep onset latency — the time it takes to fall asleep — was reduced in several subjects compared to saline controls.
- REM sleep proportion was generally maintained, suggesting DSIP did not suppress the full sleep cycle.
- Effects were more consistent in participants with disrupted baseline sleep than in those with normal sleep architecture.
A review of this early work, published through PubMed (Schoenenberger and Monnier, 1983), noted that DSIP's sleep-promoting properties in humans were modest and variable — more reliably observed in models of disturbed sleep than in healthy normal sleepers.
Research framing: These are small, early trials. They establish mechanistic plausibility but do not constitute proof of clinical efficacy for any specific indication.
Finding 2: DSIP and the Stress Response
Beyond sleep, researchers observed that DSIP modulates components of the stress response. Several studies found that DSIP influences corticotropin (ACTH) secretion and, downstream, cortisol levels.
In animal models, DSIP administration was associated with:
- Reduced plasma ACTH elevations under stress conditions
- Attenuated corticosterone increases in acute stress protocols
- Normalization of disrupted circadian corticosteroid rhythms
This stress-buffering profile aligns with the well-documented relationship between HPA axis dysregulation and sleep disruption. Elevated cortisol suppresses slow-wave sleep. A peptide that modulates cortisol output may secondarily support sleep architecture through this pathway rather than through direct soporific action.
Research available via NIH / NCBI documents these stress-response effects across multiple independent groups.
Finding 3: Analgesic Properties
A consistent finding across several DSIP studies — and one that is sometimes overlooked — is its analgesic effect in animal models.
Research across rodent pain models found that DSIP administration reduced pain sensitivity scores. The mechanism appears to involve interactions with opioid receptor pathways, though DSIP is not itself an opioid peptide.
The clinical relevance of this analgesic effect is uncertain. Most data come from preclinical models, and the doses studied do not map directly to human protocols. That said, the consistent observation across independent research groups lends some credibility to the finding.
Finding 4: Oncostatic and Antioxidant Research
Some of the more surprising DSIP research involves effects on tumor biology and oxidative stress.
In animal cancer models, DSIP and its analogues have been studied for oncostatic effects — the ability to slow abnormal cell growth. Russian researchers in the 1980s and 1990s published work suggesting DSIP reduced tumor incidence in aged rodents under carcinogen exposure protocols.
These findings should be interpreted with significant caution:
- Most studies are preclinical and from a single research tradition.
- No human clinical trials have established anticancer efficacy.
- DSIP is not used clinically for any oncological indication.
The oncostatic research is included here as part of a complete evidence picture — not as evidence of clinical effect.
Evidence Summary
| Research Area | Model | Finding | Strength of Evidence |
|---|---|---|---|
| Slow-wave sleep | Human (small trials) | Increased delta sleep in disturbed-sleep subjects | Moderate (early-stage, small N) |
| Sleep onset latency | Human / animal | Reduced time to sleep onset in several subjects | Low–Moderate |
| Stress / HPA axis | Animal | Attenuated ACTH and corticosterone under stress | Moderate (animal models) |
| Analgesia | Animal | Reduced pain sensitivity in rodent models | Moderate (preclinical) |
| Oncostatic effects | Animal | Reduced tumor incidence in aged rodents | Low (preclinical, limited replication) |
How DSIP Is Currently Studied and Used
DSIP is not approved by the FDA for any therapeutic use. It is not available as a licensed pharmaceutical in the United States. Research-grade DSIP exists in academic and compounding contexts.
Where compounded DSIP is discussed clinically, it's typically in the context of sleep quality, stress resilience, and recovery protocols. Any use is subject to evaluation by a licensed provider and is considered experimental.
At TelosRX, peptide protocols are reviewed asynchronously by a licensed clinical team. No in-person appointment is required. Compounded DSIP, if appropriate for your situation, would be subject to provider-issued prescription — approval is not guaranteed.
For a broader look at peptides studied for sleep, see our clinical team Q&A on sleep peptides. For sleep's role in hormone health, see our sleep optimization guide.
Interested in reviewing a peptide protocol with a licensed provider? Start your private evaluation at TelosRX — asynchronous, online-first, no appointment scheduling needed.
Safety and Tolerability
In the human trials conducted in the 1970s–1980s, DSIP was generally well tolerated intravenously at doses studied. No serious adverse events were reported in the published literature at research doses. However:
- Long-term safety data in humans are essentially absent.
- Most human studies involved acute or short-term administration.
- Modern subcutaneous dosing protocols for compounded DSIP are not validated by clinical trials.
- As with all compounded peptides, purity, stability, and bioavailability from compounding sources vary.
Preclinical toxicology data have not flagged significant organ toxicity at research doses, but this does not constitute a clinical safety clearance for human therapeutic use.
Frequently Asked Questions
What is DSIP peptide used for?
DSIP has been studied for sleep quality, stress resilience, and analgesic properties. It is not FDA-approved for any therapeutic use. Where used in research or compounding contexts, it's most often discussed in relation to sleep architecture support and HPA axis modulation. Any use requires evaluation by a licensed provider.
Does DSIP actually work for sleep?
Early human trials showed some improvement in slow-wave sleep and sleep onset latency, particularly in people with disrupted baseline sleep. Effects in people with normal sleep were less consistent. The evidence is preliminary and comes from small, early-phase studies. No large randomized controlled trials have been conducted.
What is the half-life of DSIP?
DSIP has a relatively short plasma half-life — estimated at roughly 30–60 minutes in animal models. Some researchers have studied DSIP analogues with extended half-lives to address this limitation. The short half-life partly explains variability in effect duration observed across studies.
Is DSIP a natural peptide?
Yes. DSIP is found naturally in the human hypothalamus, limbic system, pituitary, and blood. It's considered an endogenous neuropeptide. The synthetic version used in research and compounding has the same nine-amino-acid sequence as the natural form.
Can DSIP be combined with other peptides?
Some protocols combine DSIP with other peptides (such as Epitalon or Selank) in recovery or sleep stacks. There is no published clinical evidence specifically evaluating DSIP in combination protocols. Any stacking approach requires review by a licensed provider before use. Compounded peptides are not FDA-approved.
How does DSIP compare to other sleep peptides?
DSIP has a longer research history than most peptides marketed for sleep, dating to the 1970s. However, more recently studied peptides like Epitalon have been associated with circadian rhythm modulation through melatonin pathways. DSIP's mechanism involves slow-wave sleep induction and HPA axis effects rather than melatonin. These are distinct, potentially complementary approaches — not direct comparisons.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.